Plain-English translation of NCT07174947 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether fluoxetine, a widely used antidepressant, can make cancer immunotherapy work better in people with advanced liver or bile duct cancers. About 40% of patients with these cancers experience depression or anxiety, which may weaken their immune response. Researchers believe that treating depression with this medication while receiving immunotherapy might help the body fight cancer more effectively and improve quality of life.
Many patients with advanced liver and bile duct cancers don't respond well to immunotherapy alone, and depression or anxiety is common in these patients and may interfere with immune function. This trial explores whether treating mood symptoms alongside cancer treatment could boost the effectiveness of immunotherapy and give more patients a better chance of survival.
You likely qualify if…
You likely don't qualify if…
If you join, you will receive standard immunotherapy (the type your doctor recommends based on your cancer type) combined with fluoxetine 20 mg taken by mouth once daily. You will continue this treatment until your cancer worsens or you cannot tolerate the medication. Throughout the study, you'll have regular check-ups, blood tests, and scans to monitor how well the treatment works and how you're feeling. The research team will track your mood, anxiety, quality of life, and how your cancer responds to treatment.
AI-generated summary from trial data · Jul 5, 2026 · Not medical advice
China